Atsuko Murota1,2, Yuko Kaneko1,2, Kunihiro Yamaoka1,2, Tsutomu Takeuchi3,4. 1. From the Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan. 2. A. Murota, MD, PhD, Postdoctoral Fellow, Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine; Y. Kaneko, MD, PhD, Assistant Professor, Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine; K. Yamaoka, MD, PhD, Associate Professor, Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine; T. Takeuchi, MD, PhD, Professor, Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine. 3. From the Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan. tsutake@z5.keio.jp. 4. A. Murota, MD, PhD, Postdoctoral Fellow, Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine; Y. Kaneko, MD, PhD, Assistant Professor, Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine; K. Yamaoka, MD, PhD, Associate Professor, Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine; T. Takeuchi, MD, PhD, Professor, Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine. tsutake@z5.keio.jp.
Abstract
OBJECTIVE: To clarify the safety of biologics in elderly patients with rheumatoid arthritis. METHODS: Biologics were analyzed for safety in relation to age in 309 patients. RESULTS: Young (< 65 yrs old, n = 174), elderly (65-74 yrs old, n = 86), and older elderly patients (≥ 75 yrs old, n = 49) were enrolled. Although the incidence of adverse events causing treatment withdrawal was significantly higher in elderly and old elderly compared with young patients, no difference was found between elderly and older elderly patients. Pulmonary complications were independent risk factors. CONCLUSION: Old patients require special attention, although the safety of biologics in those ≥ 75 years old and 65-74 was comparable.
OBJECTIVE: To clarify the safety of biologics in elderly patients with rheumatoid arthritis. METHODS: Biologics were analyzed for safety in relation to age in 309 patients. RESULTS: Young (< 65 yrs old, n = 174), elderly (65-74 yrs old, n = 86), and older elderly patients (≥ 75 yrs old, n = 49) were enrolled. Although the incidence of adverse events causing treatment withdrawal was significantly higher in elderly and old elderly compared with young patients, no difference was found between elderly and older elderly patients. Pulmonary complications were independent risk factors. CONCLUSION: Old patients require special attention, although the safety of biologics in those ≥ 75 years old and 65-74 was comparable.
Authors: Mark C Genovese; Roy Fleischmann; Alan Kivitz; Eun-Bong Lee; Hubert van Hoogstraten; Toshio Kimura; Gregory St John; Erin K Mangan; Gerd R Burmester Journal: Arthritis Res Ther Date: 2020-06-10 Impact factor: 5.156
Authors: John Tesser; Shelly Kafka; Raphael J DeHoratius; Stephen Xu; Elizabeth C Hsia; Anthony Turkiewicz Journal: Arthritis Res Ther Date: 2019-08-20 Impact factor: 5.156
Authors: Roy Fleischmann; Jahangir Alam; Vipin Arora; John Bradley; Douglas E Schlichting; David Muram; Josef S Smolen Journal: RMD Open Date: 2017-10-10